As of 3:59pm ET
| +0.25 / +1.00%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 37.00 and a low estimate of 22.00. The median estimate represents a +18.34% increase from the last price of 25.35.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.